Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52245
Title: Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
Authors: Chee Khoon Lee
Chris Brown
Richard J. Gralla
Vera Hirsh
Sumitra Thongprasert
Chun Ming Tsai
Eng Huat Tan
James Chung Man Ho
Da Tong Chu
Adel Zaatar
Jemela Anne Osorio Sanchez
Vu Van Vu
Joseph Siu Kie Au
Akira Inoue
Siow Ming Lee
Val Gebski
James Chih Hsin Yang
Keywords: Biochemistry, Genetics and Molecular Biology
Medicine
Issue Date: 1-May-2013
Abstract: Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the development and progression of non-small cell lung cancer (NSCLC). We examined the impact of EGFR-tyrosine kinase inhibitors (TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients with and without EGFR mutations.MethodsRandomized trials that compared EGFR-TKIs monotherapy or combination EGFR-TKIs-chemotherapy with chemotherapy or placebo were included. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data. Pooled estimates of treatment efficacy of EGFR-TKIs for the EGFR mutation-positive (EGFRmut+) and EGFR mutation-negative (EGFRmut-) subgroups were calculated with the fixed-effects inverse variance weighted method. All statistical tests were two-sided.ResultsWe included 23 eligible trials (13 front-line, 7 second-line, 3 maintenance; n = 14570). EGFR mutation status was known in 31% of patients. EGFR-TKIs treatment prolonged PFS in EGFRmut+patients, and EGFR mutation was predictive of PFS in all settings: The front-line hazard ratio for EGFRmut+was 0.43 (95% confidence interval [CI] = 0.38 to 0.49; P <. 001), and the front-line hazard ratio for EGFRmut-was 1.06 (95% CI = 0.94 to 1.19; P =. 35; Pinteraction<. 001). The second-line hazard ratio for EGFRmut+was 0.34 (95% CI = 0.20 to 0.60; P <. 001), and the second-line hazard ratio for EGFRmut-was 1.23 (95% CI = 1.05 to 1.46; P =. 01; Pinteraction<. 001). The maintenance hazard ratio for EGFRmut+was 0.15 (95% CI = 0.08 to 0.27; P <. 001), and the maintenance hazard ratio for EGFRmut-was 0.81 (95% CI = 0.68 to 0.97; P =. 02; Pinteraction<. 001). EGFR-TKIs treatment had no impact on OS for EGFRmut+and EGFRmut-patients.ConclusionsEGFR-TKIs therapy statistically significantly delays disease progression in EGFRmut+patients but has no demonstrable impact on OS. EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment in all settings. These findings support EGFR mutation assessment before initiation of treatment. EGFR-TKIs should be considered as front-line therapy in EGFRmut+advanced NSCLC patients. © 2013 The Author.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84877291745&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/52245
ISSN: 14602105
00278874
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.